ESTRO 2024 - Abstract Book

S1953

Clinical - Mixed sites, palliation

ESTRO 2024

Bio-Medico- Oncology Center, Department of Radiation Oncology, Rome, Italy. 13 Radboud University Medical Center Nijmegen, Department of Radiation Oncology, Nijmegen, Netherlands. 14 Istituti Clinici Scientifici Maugeri, Department of Radiation Oncology, Pavia, Italy. 15 Health Research Institute Hospital Universitario de La Princesa, Department of Radiation Oncology, Madrid, Spain. 16 NHS Grampian - Aberdeen Royal Infirmary, Department of Radiation Oncology, Aberdeen, United Kingdom. 17 Hôpitaux universitaires de Genève - HUG, Department of Radiation Oncology, Genève, Switzerland. 18 RHNe - La Chaux de Fonds, Department of Radiation Oncology, La Chaux-de-Fonds, Switzerland. 19 Hospital De La Santa Creu I Sant Pau, Department of Radiation Oncology, Barcelona, Spain. 20 Iridium Network Antwerp, Department of Radiation Oncology, Antwerp, Belgium. 21 University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland

Purpose/Objective:

Stereotactic body radiotherapy (SBRT), is a guideline-recommended approach for patients with oligometastatic disease (OMD) based on evidence from randomized phase II trials which can be combined with standard-of-care systemic therapy. However, there is a knowledge gap regarding the impact of SBRT on patients' quality of life (QoL). This information is crucial for aiding both patients and clinicians in making informed decisions about the most appropriate multimodality treatment strategy.

Material/Methods:

The OligoCare study is a pragmatic prospective cohort investigation within the E²-RADIatE collaboration, a partnership between ESTRO and EORTC. Its primary objective is to identify the patient, tumor, and treatment factors that influence overall survival following radiotherapy for oligometastatic breast, colorectal, lung, and prostate cancer. The study is open to patients with various oligometastatic states (de-novo, repeat, or induced) and does not impose any restrictions on local or systemic therapy. The only requirement is that radical radiotherapy must be a component of the treatment, regardless of the maximum number of metastases, as long as all cancer lesions are treated with a radical intent. An optional component of the study involves assessing the quality of life (QoL) using the EORTC QLQ-C30 questionnaire. In this analysis, we specifically focus on evaluating the QoL at baseline and within the first six months after starting SBRT for the initial 1600 enrolled patients.

Results:

Of the first 1468 patients with at least one irradiated OMD lesion, baseline QoL assessments were completed by 530 (36.1%) patients, while 269 (18.3%) also had follow-up QoL assessments, with a median time of first follow-up assessment of three months. Approximately 70% of the patient population was male. Oligometastatic prostate cancer was the most frequent primary cancer, accounting for 44%, followed by NSCLC at 23%, breast cancer at 17%, and colorectal cancer at 16%. Overall 88% of patients had a WHO performance status (PS) of 0 or 1, with a median age of 69 years. Most patients had a single metastasis treated with SBRT, although the range of treated oligometastases ranged from 1-8. Notably, concurrent systemic treatment with radiotherapy was administered in 205 patients, which accounts for 38.7% of the total. Among these patients, 67.3% received hormonal therapy, while 19.5% were treated with chemotherapy, 15.1% received targeted therapy, and 6.3% received immunotherapy. In addition, one breast cancer patient received concomitant TDM1.